



## Share Purchase Plan – Cleansing Notice

**Melbourne, Australia (27 July 2020)**

In accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**Instrument**), Prescient Therapeutics Limited (ASX:PTX) (**Company**) gives notice that:

- (a) the Company will make offers to issue ordinary share under a share purchase plan (**SPP**) without disclosure under Part 6D.2 of the Corporations Act 2001 (Cth) (**Act**);
- (b) this notice is being given in accordance with the Instrument and in particular, paragraph 7(f)(ii) of the Instrument which requires that Company gives this notice to ASX within the 24 hour period before the SPP offer;
- (c) as at the date of this notice the Company, as a disclosing entity under the Act, has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) section 674 of the Act as it applies to the Company; and
- (d) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Act, as if this notice were a notice under section 708A(5)(e) of the Act).

– Ends –

### **About Prescient Therapeutics Limited (Prescient)**

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

#### **Cell Therapies**

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

**Cell Therapy:** Prescient has several other initiatives underway to develop new cell therapy approaches.

#### **Targeted Therapies**

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed



to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

### **COVID-19 Therapies**

Two assets are being assessed by the Doherty Institute for antiviral activity against SARS-CoV-2, the virus that causes COVID-19 disease.

Find out more at [ptxtherapeutics.com](http://ptxtherapeutics.com), or connect with us via Twitter [@PTX\\_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited have approved the release of this announcement.

#### **For more information please contact:**

**Steven Yatomi-Clarke**  
CEO & Managing Director  
Prescient Therapeutics  
[steven@ptxtherapeutics.com](mailto:steven@ptxtherapeutics.com)

**Media enquiries:**  
**Andrew Geddes – CityPR**  
+61 2 9267 4511  
[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)

---